ClinicalTrials.gg
Active, not recruitingNCT05134857Updated Jul 6, 2026

The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study

A Phase 2 interventional study of Zonisamide and Placebo in Alcohol Use Disorder (AUD), sponsored by Washington State University. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Washington State University · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
205
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies testing zonisamide in Alcoholism — none open to participants now, 1 under way, none of them phase 3. Zonisamide · Alcoholism.

Planned enrollment
Largest of 11
205 · median 40
Started
2022
the only one that year
Phase 2
6 of 11
none open now
Registered
11th of 11
by date
Lead sponsor
1 of 11
Washington State University

Among the 11 studies testing zonisamide in Alcoholism, this one has the largest planned enrollment, is the only one that started in 2022, is one of 6 in phase 2, and was the 11th registered.

Alcoholism

1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.

Browse Alcoholism studies →

Open to participants now

None of the 11 studies testing zonisamide in Alcoholism is open now. The open studies under Alcoholism, anywhere →

Where they have run

About zonisamide

Zonisamide: first FDA approval 2000 (ZONEGRAN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing zonisamide in Alcoholism as a file.
02

Study summary

A phase II randomized, double-blind, placebo-controlled clinical trial (RCT) to evaluate the ability of zonisamide (ZON) to decrease alcohol use among treatment-seeking adults with an alcohol use disorder (AUD).

Read the detailed description

This project focuses on the efficacy of a promising pharmacotherapy (ZON) for AUDs using a placebo-controlled design that will rigorously measure alcohol use and medication adherence. Results will guide novel mechanistic targets to better capture the heterogeneity within AUDs. This project will evaluate the ability of ZON to treat the alcohol use disorder.

The investigators hypothesize that the group assigned to ZON associated with the standard treatment (ZON+ST) will yield lower rates of biochemically verified alcohol use, fewer self-reported drinks per day, and fewer heavy drinking days during the 12-week treatment and 1-year follow-up periods, relative to the placebo associated with the standard treatment (PLO+ST) group.

03

Conditions studied

  • Alcohol Use Disorder (AUD)

Browse trials for

Keywords

  • Alcohol Use Disorder
  • Zonisamide
  • Contingency Management
  • Incentives for Sobriety
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Four or more standard drinks on four or more occasions in the prior 30 days.
  2. Seeking AUD treatment.
  3. Aged 18-65 years.
  4. diagnosis of AUD.
  5. Ability to read and speak English.
  6. Ability to provide written .
  7. Breath alcohol of 0.00 during informed consent.
  8. Provision of at least 1 EtG-positive urine test at any time during the induction period.
  9. Non-lactating women of childbearing age using reliable form of with a negative urine pregnancy test at baseline, and
  10. Attended at least 4 of 6 visits during the induction period.

Exclusion criteria

Exclusion Criteria:

  1. Significant risk of dangerous alcohol withdrawal, defined as a history of alcohol detoxification or seizure in the last 12 months and expression of concern by the participant about dangerous withdrawal;
  2. Currently receiving any pharmacotherapy for alcohol or in the past 30 days.
  3. Current diagnosis of severe substance use disorder other than nicotine.
  4. Suicide attempt in the last 20 years.
  5. History of to sulfonamide medication, Stevens-Johnson Syndrome, penicillin allergy or allergic reaction to any drug
  6. Systemic disease.
  7. History of current seizure disorder (e.g., are they receiving medication currently for their seizures, have they ever been told by their provider that they have epilepsy, or do they have a history of recurring seizures in the last 5 years?).
  8. Current blood dyscrasia.
  9. History of clinically significant renal calculi or renal failure; renal compromise (defined by an elevation of serum creatinine above our laboratory's limit of normal).
  10. History of traumatic brain injury (TBI; e.g., ever been told by a provider that they had a moderate or severe TBI, lost consciousness for 30 minutes or longer or had a post-traumatic amnesia lasting a day or longer).
  11. Any other current, clinically significant physical disease [i.e., neurologic, renal, rheumatologic, gastrointestinal, hematologic, pulmonary, endocrine, cardiovascular, hepatic, or autoimmune disease] on the basis of medical history, physical examination, or routine laboratory evaluation that, in the context of the study would represent a risk to the subject, or significant laboratory abnormalities related to hepatic function such as marked elevations of hepatic aminotransferase levels (i.e., and ALT) or direct , and
  12. Any other medical or psychiatric condition that Dr. Rodin determines would compromise safe participation.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
205 participants (estimated)

Study arms

  • Experimental
    ZON+ST

    Zonisamide (ZON) plus standard treatment (ST)

    Drug: Zonisamide

  • Placebo comparator
    PLO+ST

    Placebo (PLO) plus standard treatment (ST)

    Drug: Placebo

Interventions

  • The ZON will be supplied in 100 mg capsules and deposited directly into the TAD device by research staff every 2 weeks. All participants will be told to take 100 mg/day for the first three weeks (Week 1-2 single-blind, placebo-only, induction; end of Week 2, active treatment begins) and increasing by 100 mg/day every other week (Week 4: 200 mg/day; Week 6: 300 mg/day; Week 8: 400 mg/day) up to the target dose of 500 mg/day by Week 10. The participants will be maintained on this dose through Week 14 of active treatment and then tapered off ZON (2 weeks). This dosing schedule is consistent with best practices for ZON. All TAD devices will only dispense the prescribed medication between 4pm and 11pm each night. Participants will be instructed to take the medication at or near bedtime.

  • DrugPlacebo

    The PLO will be supplied at the same schedule and in the same manner (TAD device) as the ZON.

06

What researchers measure

Primary outcomes

  1. Change in Self Reported Alcohol Consumption

    Consumption of alcohol between participants randomized to ZON+ST vs PLO+ST assessed by participant self report (collected 1x weekly from weeks 1-14 and once at weeks 18, 38, and 54).

    Time frame: 12-week treatment and 1-year follow-up period

Secondary outcomes

  1. Change in Biochemically Verified Alcohol Consumption

    Consumption of alcohol between participants randomized to ZON+ST vs PLO+ST assessed by alcohol breathalyzer and biochemical EtG values (collected 3x weekly from weeks 1-6, 1x weekly at weeks 7-14, and once at weeks 18, 38, and 54).

    Time frame: 12-week treatment and 1-year follow-up period

Other outcomes

  1. Adverse Events

    Occurrence of adverse events assessed by SAFETEE (collected 3x weekly at weeks 1-6, 1x weekly at weeks 7-14, and once at weeks 18, 38, and 54).

    Time frame: 12-week treatment and 1-year follow-up period

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Data is to be shared with NIAAA under their required data archiving procedures.

Supporting information: Clinical study report

Time frame: 5-6 years

Access criteria: Determined by NIAAA data archive policy

Data sharing details ↗ · www.niaaa.nih.gov

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Aug 2027, 67 months after the start.

Of 123 non-industry phase 2 interventional studies under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 59. This study's planned 67 months is above that.

Counting every sponsor, half of 135 studies reached it within 33 months; a quarter within 21 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2021
First posted
Nov 26, 2021
StartActual
Jan 7, 2022
Primary completionEst.
Aug 31, 2027
CompletionEst.
Aug 31, 2027
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05134857
Lead sponsor
Washington State University
Responsible party
Sterling McPherson (Professor, Washington State University) — Principal investigator
First posted
Nov 26, 2021
Start date
Jan 7, 2022
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Jul 6, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zonisamide

Start the discussion